Phase III trials of LY 2189265 (Eli Lilly) show safety and efficacy benefits in Type 2 Diabetes

Results from three Phase III AWARD trials for LY 2189265 (dulaglutide), from Eli Lilly, for Type 2 Diabetes showed the drug was superior to placebo and to exenatide (AWARD-1), metformin (AWARD-3) and sitagliptin (AWARD-5) in reducing HbA1c (hemoglobin A1c) levels. In addition, a greater percentage of patients treated with dulaglutide achieved an HbA1c goal of less than 7% versus all active comparators.

Patients taking dulaglutide also showed significant weight loss compared to patients taking sitagliptin (AWARD-5), and showed similar weight loss to patients taking comparators in AWARD-1 and AWARD-3. AWARD-1 and 3 are 52 week trials of 978 and 807 patients, respectively. AWARD-5 is a 104 week trial of 1,098 patients. Data were presented today at the 73rd American Diabetes Association Scientific Sessions.